Disclosed herein are CD40-targetting antibodies and uses thereof. Disclosed herein are novel antigen-binding proteins that specifically bind CD40 and antigen-binding fragments thereof. Disclosed herein are also fusion proteins comprising a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) and a second domain that activates an immune effector cell (e.g., a T cell), wherein the first domain comprises antigen-binding proteins that specifically bind CD40 or antigen-binding fragments thereof disclosed herein.